Dr Jason Yap BSc (Hons), MBBS, MRCOG, PhD

Dr Jason Yap

Institute of Cancer and Genomic Sciences
NIHR funded Academic Clinical Lecturer

Contact details

Institute of Cancer and Genomic Sciences
College of Medical and Dental Sciences
University of Birmingham
B15 2TT

Jason is an NIHR-funded Academic Clinical Lecturer in Gynaecological Oncology working at the Institute of Cancer and Genomic Sciences.

He leads a laboratory-based research group and has developed a stream of translational research relating to the pathogenesis and treatment of two gynaecological malignancies: vulval neoplasia and ovarian cancer. He is also a joint principal investigator for a phase II clinical trial investigating the effectiveness of EGCG, a green tea polyphenol, in the treatment of vulvar intraepithelial neoplasia (VIN), a premalignant lesion of the vulva.

Jason has received funding from Cancer Research UK, The Pathology Society, The National Institute of Health Research, The Royal College of Obstetricians and Gynaecologists and OVACOME ovarian cancer charity.


  • PhD in Cancer Studies, University of Birmingham, 2016
  • Member of the Royal College of Obstetricians and Gynaecologists (MRCOG), 2010
  • Bachelor of Medicine, Bachelor of Surgery (MBBS), University College London, 2005
  • Intercalated BSc degree in Pharmacology, University College London, 2002


Jason studied medicine at University College London, UK, graduating in 2005 with an award in the subject of Obstetrics and Gynaecology. He completed his Foundation Doctor training in the North London Deanery and was then appointed into the Specialist Training Programme in Obstetrics and Gynaecology in 2007 by the West Midlands Deanery. 

In 2012, he was awarded a Clinical Research Training Fellowship by Cancer Research UK and undertook a three-year laboratory-based PhD study in translational cancer biology with Prof. Ciaran Woodman at the Institute of Cancer Sciences, University of Birmingham.

Upon completing his PhD, he was appointed as an NIHR-funded Academic Clinical Lecturer in 2016. His translational research focuses on improving treatment outcomes for women with pre-malignant and malignant disease of the vulva, and high grade serous ovarian cancer. 

In 2016, he was awarded the William Blaire Bell Research Fellowship by the Royal College of Obstetricians and Gynaecologists, UK, for his research into the pathobiology of vulval cancer. Jason is also a joint Principal Investigator for an NIHR-funded phase II clinical trial, EPIVIN, which evaluates the effectiveness of novel topical therapy for women with vulvar intraepithelial neoplasia (uVIN). 

Together with Professor Paul Moss and his mentor, Professor Sean Kehoe, Jason has begun to explore the relationship between tumour cells and their microenvironment (TME) in high-grade serous ovarian cancer (HGSOC) with a specific focus on infiltrating immune cells and how ovarian cancer evades host cell immunity.

He is passionate about understanding the pathobiology of vulval neoplasia and ovarian cancer and utilises his knowledge in basic sciences to develop better treatment for his patients.


  • MB ChB 2nd year tutor for Cancer: Causes to Cures module - cancer epidemiology
  • MB ChB 2nd year tutor for Cancer: Causes to Cures module - from mutation to treatment
  • MB ChB clinical tutor for Obstetrics and Gynaecology and Clinical Oncology modules
  • Mentor for PhD student in Institute of Cancer and Genomic Sciences

Postgraduate supervision

  • MRes students in laboratory based projects
  • PhD student in laboratory and clinical based projects


Jason’s research focuses mainly on improving the outcome of women with vulval neoplasia and ovarian cancer, translating fundamental laboratory discoveries into clinical practice and vice versa. 

His research is divided into two main disciplines as follow: 

Basic Science (Translational Research) 

High grade serous ovarian cancer:

  • Interrogating the relationship between tumour microenvironment and its infiltrating immune cells in high-grade serous ovarian cancer. 

Vulvar neoplasia:

  • Understanding the “cancer field” effect in squamous cell carcinoma of the vulva.
  • Epigallocathecin-3-gallate (EGCG), a potential therapy for HPV-positive vulvar intraepithelial neoplasia (uVIN).
  • The Sonic Hedgehog pathway: a potential molecular therapeutic target for vulvar neoplasia. 

Advanced tissue culture techniques:

  • Organotypic raft culture
  • Ovarian cancer organoid culture 

Clinical studies

  • Phase II randomised control trial evaluating the use of topical Epigallocathecin-3-gallate in the treatment of women with vulvar intraepithelial neoplasia.
  • Cohort, cross-sectional and prospective clinical studies in pre-invasive and invasive disease of the vulva and high-grade serous ovarian cancer.

Other activities

  • Member of the Birmingham Vulvar Neoplasia Study Group
  • Co-Chair of West Midlands vulval disease MDT


Yap J., Fox R., Narsia N., Pinheiro-Maia S., Pounds R., Woodman C., Luesley D., Ganesan R., Kehoe S., Dawson C. Under expression of the Sonic Hedgehog receptor, Patched1 (PTCH1), is associated with an increased risk of local recurrence in squamous cell carcinoma of the vulva arising on a background of Lichen Sclerosus. PLoS One. 2018 Oct 31;13(10):e0206553. doi: 10.1371/journal.pone.0206553.

Yap, J., O’Neill, D., Nagenthiran, S., Dawson, C., Luesley, D. Current insights into the aetiology, pathobiology and management of local disease recurrence in squamous cell carcinoma of the vulva: a review paper. British Journal of Obtetrics and Gynaecology (2017) Article in Press (DOI: 10.1111/1471-0528.14560)

Yap, J. K., Fox, R., Leonard, S., Ganesan, R., Kehoe, S. T., Dawson, C. W., Woodman, C. B., and Luesley, D. M. (2016) Adjacent Lichen Sclerosis predicts local recurrence and second field tumour in women with vulvar squamous cell carcinoma. Gynecologic Oncology 142, 420-426 (Society White Paper)

Leonard, S., Pereira, M., Fox, R., Gordon, N., Yap, J., Kehoe, S., Luesley, D., Woodman, C., and Ganesan, R. (2016) Over-expression of DNMT3A predicts the risk of recurrent vulvar squamous cell carcinomas. Gynecologic Oncology

Soo Hoo, S., Marriott, N., Houlton, A., Nevin, J., Balega, J., Singh, K., Yap, J., Sethuram, R., Elattar, A., Luesley, D., Kehoe, S., and Sundar, S. (2015) Patient-Reported Outcomes After Extensive (Ultraradical) Surgery for Ovarian Cancer: Results From a Prospective Longitudinal Feasibility Study. International Journal of Gynecological Cancer : official journal of the International Gynecological Cancer Society 25, 1599-1607

Underwood, M., Yap, J. K., Elattar, A., Ganesan, R., Notghi, A., Crockett, C., and Luesley, D. M. (2013) The use of sentinel node sampling in vulval cancer. J Obstet Gynaecol 33, 892-897

Gallos, I. D., Yap, J., Rajkhowa, M., Luesley, D. M., Coomarasamy, A., and Gupta, J. K. (2012) Regression, relapse, and live birth rates with fertility-sparing therapy for endometrial cancer and atypical complex endometrial hyperplasia: a systematic review and metaanalysis. American Journal of Obstetrics and Gynecology 207, 266 e261-212

Sundar, S., Wu, J., Hillaby, K., Yap, J., and Lilford, R. (2012) A systematic review evaluating the relationship between progression free survival and post progression survival in advanced ovarian cancer. Gynecologic Oncology 125, 493-499

Yap, J. K., Baker, L. J., Balega, J. Z., Chan, K. K., and Luesley, D. M. (2011) Impact of improving outcome guidance in gynaecological cancer on squamous cell carcinoma of the vulva in the West Midlands, UK. J Obstet Gynaecol 31, 754-758

Yap, J. K., and Davies, M. (2007) Fertility preservation in female cancer survivors. J Obstet Gynaecol 27, 390-400